Tenecteplase (1 brand name, 1 dosage form, 0 routes)
Available dosage forms: VIAL.
Brand Names
- TNKASE
Adverse Reactions
The following clinically significant adverse reactions are discussed in other sections of the label: Bleeding [see Contraindications (4), Warnings and Precautions (5.1)] Hypersensitivity [see Warnings and Precautions (5.2)] Thromboembolism [see Warnings and Precautions (5.3)] Cholesterol Embolization [see Warnings and Precautions (5.4)] Arrhythmias [see Warnings and Precautions (5.5)] Increased Risk of Heart Failure and Recurrent Ischemia when used with Planned Percutaneous Coronary Intervention (PCI) in STEMI [see Warnings and Precautions (5.6)]
Mechanism of Action
Tenecteplase is a modified form of human tissue plasminogen activator (tPA) that binds to fibrin and converts plasminogen to plasmin. In the presence of fibrin, in vitro studies demonstrate that tenecteplase-mediated conversion of plasminogen to plasmin is increased relative to its conversion in the absence of fibrin. This fibrin specificity decreases systemic activation of plasminogen and the resulting degradation of circulating fibrinogen as compared to a molecule lacking this property. The clinical significance of fibrin-specificity on safety (e.g., bleeding) or efficacy has not been established.